Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors.

“Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization,” said Sanjeev Luther, President and CEO of Eterna. “We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineering.”

Mr. Cicala's professional expertise focuses on all aspects of pharmaceutical and biotechnology intellectual property and strategic management of proprietary technology and products. His most recent experience involves advising start-up and venture-backed biotechnology companies through all aspects of drug development and the protection of proprietary technologies, including long-range strategic planning and commercialization of therapeutics.

“I’m excited to join Eterna’s Board at such a pivotal and exciting time for the company,” said Mr. Cicala. “Eterna’s impressive technology and potential to revolutionize medicine through mRNA cell engineering is truly groundbreaking. I’m looking forward to working toward continued growth and success.”

Mr. Cicala has extensive experience in patent litigation, prosecution, product lifecycle management, R&D collaborations, M&A transactions, and joint ventures in the pharma/biotech industry, including small molecule, antibody and CAR-T products. Mr. Cicala has substantial experience with patent and regulatory litigation in most major pharmaceutical markets. Additionally, Mr. Cicala has over ten years of experience as a medicinal chemist and has worked on drug development programs for several major pharmaceutical companies and universities.

Mr. Cicala graduated from Seton Hall University School of Law and has a Bachelor of Science in Chemistry from Fairleigh Dickinson University.

About Eterna Therapeutics Inc.
Eterna Therapeutics is a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 130 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system from Factor Bioscience. NoveSlice, UltraSlice, and ToRNAdo are trademarks of Factor Bioscience. For more information, please visit www.eternatx.com.